A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes

Phase 4 Recruiting 204 enrolled Boryung Pharmaceutical Co., Ltd

RandomizedParallel-groupOpen-labelTreatment

Summary

This is a randomized, open-label, active-controlled, parallel, multicenter, phase IV clinical study evaluating the efficacy and safety of switching Metformin+SGLT2-i+DPP4-i to Metformin+SGLT2-i+TZD in patients with type 2 diabetes.

Timeline

Start: 2025-06-11
Primary completion: 2026-10-01
Completion: 2026-10-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Pioglitazone	Small molecule	30 mg	Oral
Comparator	Sitagliptin	Small molecule	100 mg	Oral
Background	Dapagliflozin	Small molecule	10 mg	Oral
Background	Metformin	Small molecule	—	Oral

A Phase IV Clinical Trial to Compare the Efficacy and Safety of Metformin+Sodium-Glucose Cotransporter 2 Inhibitor(SGLT2-i)+Thiazolidinedione (TZD) in Patients With Type 2 Diabetes

Summary

Timeline

Drugs

Indications